Absci (ABSI) and Invetx announced a strategic partnership to harness Absci’s AI Drug Creation models to create an innovative Half-Life Extension, HLE, platform for animal health applications. Under the terms of the agreement, Absci will utilize its AI models to design novel modular antibody sequences that confer Half-Life Extension in specific animal species, Invetx will have rights, subject to the agreement’s financial and other terms, to use the HLE platform in multiple products to enhance duration of therapeutic effect and customer convenience, both significant potential differentiators in the animal health market. The partnership includes R&D funding, as well as election fees, milestone payments, and royalties on a per-product basis.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci highlights progress, updates across proprietary pipeline
- Cathie Wood’s ARK Investment bought 202.6K shares of Absci today
- Cathie Wood’s ARK Investment bought 137.9K shares of Absci today
- Absci initiated with a Buy at JonesResearch
- Cathie Wood’s ARK Investment bought 400.3K shares of Absci today